Investment
Features
FeesSafety
Academy
More
Pluang+

Compare RingCentral Inc. Class A Common Stock (RNG) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

RingCentral Inc. Class A Common StockTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

RingCentral Inc. Class A Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? RingCentral Inc. Class A Common Stock trades at $75.22 (market cap $6.53B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: RingCentral Inc. Class A Common Stock is far larger — about 3.6× Vir Biotechnology Inc. Common Stock's market cap, and RingCentral Inc. Class A Common Stock pays a 0.35% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold RingCentral Inc. Class A Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

RNGVIR
Market Cap
$6.53B$1.80B
Volume
1,430,5041,782,836
Sector
TechnologyHealth
52-Week High
$79.82$11.78
52-Week Low
$24.82$5.12
Typical Hold Time
6 Days0 Days
Enterprise Value
$7.58B$1.36B
Dividend Yield
0.35%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

RingCentral Inc. Class A Common Stock

RingCentral (RNG) trades at $78.69, up 0.67% on the day and near its 52-week high, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend. Fundamentally, the company shows revenue growth to $2.52 billion in 2025, with net income of $43.39 million and improving margins. Recent earnings beats and strategic AI partnerships, like the one with Allnet.Italia announced October 13, 2026, underscore growth potential. Analyst sentiment is overwhelmingly positive with 28 buy ratings and a consensus price target of $61.00, though the current price exceeds this target.

The outlook for RNG is favorable driven by AI integration and earnings momentum, but risks include high valuation with a P/E of 62.54 and potential volatility ahead of Q3 2026 results on October 22, 2026. Investor focus remains on execution and margin expansion amid competitive pressures.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RNG

No sentiment data available yet.

VIR
51% Buy49% Sell
Avg holding period · 0 Days

About RingCentral Inc. Class A Common Stock

RingCentral provides cloud-based business communications and contact center solutions. Its platform combines phone, messaging, video meetings, and customer-service tools.

Read more on RNG →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →